Posters/Publications

August 27, 2020 in NASH

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

(Oral presentation, EASL International Liver Congress, 27-29 August 2020, Abstract #AS074)
Read More
August 27, 2020 in NASH

The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH

(Poster, EASL International Liver Congress, 27-29 August 2020, Abstract #SAT038)
Read More
December 18, 2019 in NASH

First‐in‐class fatty acid synthase inhibitor TVB‐2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities

(Paper, Hepatology 2020)
Read More
September 6, 2019 in NASH

Fibroblast Growth Factor-21 and its Relationship to Human Liver Fat Synthesis; Impact of a New Therapeutic Agent

(Poster, Obesity Week, 11-15 November 2018, Abstract # T-P-3383)
Read More
September 5, 2019 in NASH

The FASN inhibitor, TVB3664, Ameliorates NASH in a Murine Model

(Poster, AASLD The Liver Meeting, 9-13 November 2018, Abstract #734)
Read More
September 3, 2019 in NASH

Updated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab

(Poster, ASCO Annual Meeting, 31 May – 4 June 2019, Abstract #2064)
Read More
February 13, 2018 in NASH

Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN

(Presented at the Keystone Symposium on Organ Crosstalk in Obesity and NAFLD, Jan. 21-25, 2018 Keystone, CO, Poster #3028)
Read More
May 2, 2017 in NASH

Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for NASH treatment

(Presented at The International Liver Congress, Amsterdam, NL April 18-23, 2017, Late Breaking Abstract LB427)
Read More
October 23, 2017 in Oncology

Fatty Acid Synthase Inhibitor TVB-3664 Reverses Multiple Components of Diet Induced Nonalcoholic Steatohepatitis in Mice Treated With or Without Co-Administered Pirfenidone and Reduces Collagen Accumulation in Bleomycin-Induced Murine Skin Fibrosis.

(Presented at The Liver Meeting 2017®, Washington, DC, Oct 20-24, Presidential Poster of Distinction, Abstract #1994)
Read More
October 23, 2017 in Oncology

Pharmacologic Inhibition of FASN Reverses Diet-Induced Steatohepatitis in Mice and Inhibits Lipogenesis in Humans.

(Presented at The Liver Meeting 2017®, Washington, DC, Oct 20-24, Abstract #1972)
Read More
December 12, 2016 in Oncology

Heavily Pre-Treated Breast Cancer Patients Show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640 in Combination with Paclitaxel.

(Presented at the San Antonio Breast Cancer Symposium on Saturday Dec. 10, 2016, abstract number P6-11-09)
Read More
November 11, 2016 in Oncology

Pharmacological inhibition of FASN Prevents High Fat Diet Induced Liver Damage in Mice and Significantly Reduces de novo Lipogenesis in Humans

(Presidential Poster of Distinction presented at the AASLD Meeting on Sunday November 13, 2016, Abstract #1547)
Read More
November 8, 2016 in Oncology

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase Inhibitor, TVB-2640

(Presented at the NCRI Cancer Conference on Tuesday Nov. 8, 2016)
Read More
June 1, 2016 in Oncology

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

(Poster and Poster Discussion Sessions at the ASCO Meeting on Sunday June 5, 2016, Abstract #2512, Board #212)
Read More
April 19, 2016 in Oncology

FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS-mutant NSCLC patients in a phase I study

(Poster Presentation at AACR Meeting on Monday Apr 18, 2016 1:00 PM, Abstract number LB-214)
Read More
April 19, 2016 in Oncology

Preclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel drug combinations with TVB-2640

(Poster Presentation at AACR Meeting on Wednesday, April 20, 2016, Abstract number 4743)
Read More
March 24, 2016 in Oncology

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

(Presented by Dr. Manish Patel at the Targeted Anticancer Therapies (TAT) Congress on Wednesday March 23, 2016 at 12 noon EDT)
Read More
March 2, 2016 in Oncology

Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement

(Abstract #1022 and Short Presentation at Keystone Symposium, “New Frontiers in Understanding Tumor Metabolism” February 21-25, 2016, Banff, Alberta, Canada)
Read More
November 8, 2015 in Oncology

FASN inhibition studies in preclinical tumor models identify biomarkers that align with in vitro and in vivo sensitivity to TVB-2640

(Poster Presentation at AACR-NCI-EORTC meeting on Sunday Nov 8, 2015)
Read More
November 7, 2015 in Oncology

Biomarker Analyses from Dose Escalation Phase of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients

(Poster presented at AACR-NCI-EORTC Meeting on Saturday, Nov 7, 2015)
Read More